SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+metastatic breast cancer (MBC).

被引：7
|
作者：
Rugo, Hope S.
Pegram, Mark D.
Gradishar, William John
Cortes, Javier
Curigliano, Giuseppe
Wigginton, Jon M.
Lechleider, Robert Joseph
Cardoso, Fatima
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94132 USA
[2] Stanford Sch Med, Stanford, CA 94305 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Vall Hebron Inst Oncol, Barcelona, Spain
[5] Ist Europeo Oncol, Milan, Italy
[6] MacroGen Inc, Rockville, MD USA
[7] Champalimaud Canc Ctr, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS630
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A single-centre phase 2 study of vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer (MBC)
    De Maio, E.
    Pacilio, C.
    Gravina, A.
    Nuzzo, F.
    Di Rella, F.
    Labonia, V
    Landi, G.
    Rossi, E.
    Silvestro, P.
    Maurea, N.
    Botti, G.
    Di Bonito, M.
    La Vecchia, F.
    Staiano, M.
    D'Aiuto, G.
    Di Maio, M.
    Morabito, A.
    Perrone, F.
    De Matteis, A.
    ANNALS OF ONCOLOGY, 2006, 17 : XI11 - XI11
  • [42] FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
    Royce, Melanie
    Osgood, Christy L.
    Amatya, Anup K.
    Fiero, Mallorie H.
    Chang, C. J. George
    Ricks, Tiffany K.
    Shetty, Krithika A.
    Kraft, Jeffrey
    Qiu, Junshan
    Song, Pengfei
    Charlab, Rosane
    Yu, Jingyu
    King, Kathryn E.
    Rastogi, Anshu
    Janelsins, Brian
    Weinberg, Wendy C.
    Clouse, Kathleen
    Borders-Hemphill, Vicky
    Brown, Lindsey
    Gomez-Broughton, Candace
    Li, Zhong
    Thuy Thanh Nguyen
    Qiu, Zhihao
    Anh-Thy Ly
    Chang, Suyoung
    Gao, Tingting
    Tu, Chi-Ming
    King-Kallimanis, Bellinda
    Pierce, William F.
    Chiang, Kelly
    Lee, Clara
    Goldberg, Kirsten B.
    Leighton, John K.
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1487 - 1492
  • [43] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [44] Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+metastatic breast cancer (MBC).
    De La Pena, Lorena
    Cortes, Javier
    Manikhas, Alexey
    Roman, Laslo
    Semiglazov, Vladimir
    Biakhov, Mikhail Yu
    Dasappa, Lokanatha
    Llombart, Antonio
    Rozencweig, Marcel
    Forenza, Salvatore
    Goldfarb, Ronald H.
    Matera, Jeri
    Azarnia, Nozar
    Hudis, Clifford
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [46] Treatment patterns following first-line pertuzumab plus trastuzumab in patients with HER2+metastatic breast cancer in the United States.
    Mehta, Sandhya
    Pavilack, Melissa
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Lei, Yin
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
    Hurvitz, Sara
    Kim, Sung-Bae
    Chung, Wei-Pang
    Im, Seock-Ah
    Park, Yeon Hee
    Hegg, Roberto
    Kim, Min-Hwan
    Tseng, Ling-Ming
    Petry, Vanessa
    Chung, Chi-Feng
    Iwata, Hiroji
    Hamilton, Erika
    Curigliano, Giuseppe
    Xu, Binghe
    Lee, Caleb
    Liu, Yali
    Cathcart, Jillian
    Bako, Emarjola
    Verma, Sunil
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [48] TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Gavila, Joaquin
    Bermejo, Begona
    Rodriguez-Lescure, Alvaro
    Lao Romera, Juan
    Manso, Luis
    Brunet, Joan
    Munoz, Eva
    Santisteban, Marta
    Rodriguez, Cesar A.
    Santaballa, Ana
    de la Haba, Juan
    Sanchez-Rovira, Pedro
    Ruiz-Borrego, Manuel
    Angel Garcia-Saenz, Jose
    Cortes, Javier
    Llombart, Antonio
    CANCER RESEARCH, 2015, 75
  • [49] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [50] Second-line treatment of HER2+metastatic breast cancer (MBC): Trastuzumab (T) beyond progression or lapatinib (L)? A retrospective database study
    Yerushalmi, Rinat
    Feldhamer, Ilan
    Greenberg-Dotan, Sari
    Bitterman, Haim
    Hammerman, Ariel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345